Form 4: Evoke Pharma Director Kenneth J. Widder Reports Stock Option Grant

Director Kenneth J. Widder reports the acquisition of stock options in Evoke Pharma, Inc.

Summary

• Kenneth J. Widder, a director of Evoke Pharma Inc, filed a Form 4 with the SEC.
• The filing reports the grant of stock options to Widder on May 21, 2025.
• The options allow Widder to purchase 1,187 shares of Evoke Pharma's common stock at an exercise price of $3.453 per share.
• The options vest one year from the grant date, contingent upon Widder's continued service to the company.
• Following the transaction, Widder directly owns 8,207 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It simply reports a transaction.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency into the equity-based compensation of company directors.

Stakeholder Impact

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing them to increase the company's value.

Key Dates

Keywords

Form 4, Evoke Pharma, Stock Options, Beneficial Ownership, Director, EVOK, Widder